A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Characteristics of Multiple Doses of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
Latest Information Update: 29 Apr 2026
At a glance
- Drugs LY 03015 (Primary)
- Indications Tardive dyskinesia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Luye Pharma Group
Most Recent Events
- 31 Mar 2026 According to Luye Pharma Group media release, the company is expected to obtain the data of a Phase 2 clinical trial conducted in China by mid-2026
- 28 Aug 2025 According to Luye Pharma Group media release, this trial is expected to be completed by the end of 2025 and deliver the data on efficacy in the first half of 2026.
- 22 Jan 2025 Status changed from not yet recruiting to recruiting.